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Abstract
Background: Tuberculosis is considered the second most common cause of death due to infectious agent. The
currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and
ethambutol, which has been used either as separate tablets (ST) or as fixed-dose combination (FDC). To date, no
studies have compared both regimens in Qatar. We aim to evaluate the safety and effectiveness of FDC and ST
regimen for treating PTB, in addition to comparing safety and efficacy of FDC and ST regimens in patients with
diabetes treated for TB.
Methods: A retrospective observational study was conducted in two general hospitals in Qatar. Patients diagnosed
with PTB received anti-tuberculosis medications (either as FDC or ST) administered by the nurse. Sputum smears
were tested weekly. We assessed the time to negative sputum smear and incidence of adverse events among FDC
and ST groups.
Results: The study included 148 patients. FDC was used in 90 patients (61%). Effectiveness was not different
between FDC and ST regimens as shown by mean time to sputum conversion (29.9 ± 18.3 vs. 35.6 ± 23 days, p = 0.12).
Similarly, there was no difference in the incidence of adverse events, except for visual one that was higher in ST group.
Among the 33 diabetic patients, 19 received the FDC and had faster sputum conversion compared to those who
received ST (31 ± 12 vs. 49.4 ± 30.9 days, p = 0.05). Overall, diabetic patients needed longer time for sputum conversion
and had more hepatotoxic and gastric adverse events compared to non-diabetics.
Conclusion: ST group had higher visual side effects compared to FDC. FDC may be more effective in diabetic patients;
however, further studies are required to confirm such finding.
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Background
Tuberculosis (TB) is the second greatest worldwide infec-
tious killer. According to the World Health Organization
(WHO), 37 million lives were treated between 2000 and
2013. In 2014, 9.6 million people fell ill with TB [1]. Qatar
is a peninsula located between the Persian Gulf and Saudi
Arabia [2]. In January 2016, the population was estimated
to be over 2.3 million compared to around 220 thousands
in the mid-1980s. This increase was primarily driven by
the expatriate workforce traveling to Qatar. In 2013, num-
ber of foreign labors constituted around 85.7% of the
population and up to 94.1% of the country’s workforce [3].
The majority of this workforce is from Asian countries
with high TB prevalence such as India (31%), Nepal (23%),
Bangladesh (4.8%) leading to an increase in the total num-
ber of TB [3]. In Qatar, all cases of TB are registered at
the Communicable Disease Control and Prevention Sec-
tion in the Supreme Council of Health [4]. TB cases have
increased from 184 cases in 1990 to 728 cases in 2012
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with a decrease in the incidence rate from 44/100,000 to
41/100,000. A decrease in the incidence of TB was re-
corded at 40/100,000 with 511 new cases [5]. Mycobacter-
ium tuberculosis is the bacteria responsible for TB and it
spreads through the air leading to lung infection which is
the most common TB infection. Even though TB is
preventable and curable, achieving a high cure rate is
challenging and critical. The usual TB treatment regimen
is a standard 2-month regimen of isoniazid (INH), rifam-
pin (RIF), pyrazinamide (PZA), and ethambutol (EMB),
followed by a 4-month regimen of isoniazid and rifampin.
This classic regimen is associated with poor compliance
and adherence which leads to the development of resistant
strains and multidrug resistant bacilli [6]. Several methods
have been explored to improve compliance and reduce er-
rors such as the fixed-dose combination (FDC). The ra-
tionale of FDC is that the presence of all these drugs
combined in one tablet can facilitate dosage calculation,
prevent prescribing errors, increases patient’s acceptance,
and decreases pill burden [7–9]. During the 1980s and
1990s, health care providers were concerned about the
quality of FDCs where poor bioavailability of the rifampin
component of the tablet was an issue [10, 11]. However,
current FDCs are fully bioequivalent, stable and efficacious
even after 6 months in tropical conditions [7, 12–17].
Common fixed-dose combinations (FDCs) are of two anti-
tuberculosis drugs (2FDCs, usually [RIF] + [INH]), three
drugs (3FDCs, RIF + INH + [PZA]) and four drugs
(4FDCs, RIF + INH+ PZA + [EMB]). Several studies tested
the safety and efficacy in different parts of the world using
different brands of FDC regimens. However, no similar
studies were performed in Qatar.
The objective of this study is to compare the FDC
using Rifafour® for the first time as part of an FDC regi-
men and compare it to the regimens of separate tablets
(ST) during the initial phase of TB treatment in Qatar,
while assessing the safety and effectiveness of both regi-
mens in terms of adverse events and time to negative
sputum smear, respectively. The secondary objective is
to compare FDC to ST regimens in terms of safety and
efficacy in patients with diabetes treated for TB.
Methods
Study settings
This study was performed in two general hospitals in
Qatar, with a total of 450 beds. Pulmonary tuberculosis
(PTB) patients were diagnosed based on their symptoms,
chest X-rays, and sputum smears. Once diagnosis was
confirmed by positive sputum smear, patients were kept
in isolation rooms within the hospital until their sputum
smears became negative, confirmed by two consecutive
smears. Medical teams started patients on first-line anti-
TB medications (RIF, INH, PZA, and EMB), either as
FDC (Rifafour® [Sanofi-Aventis]: RIF 150, INH 75, PZA
400, and EMB 275 mg/tablet) or ST (RIF 150, INH 100
or 300, PZA 500, and EMB 400 or 500 mg/tablet), ad-
ministered by the nurse early morning on empty
stomach. The dose was calculated based on the patient’s
weight. Table 1 shows the daily doses by body weight
category for each regimen. Choice of the regimen was
based on the introduction of the FDC in June 2013, at
that time physicians started prescribing the FDC for
most patients. Patients received pyridoxine 40 mg orally
once daily along with anti-TB medications. Diabetes
was controlled during the hospital stay with oral
hypoglycemic agents and/or insulin, along with regular
random blood sugar monitoring. Also, hypertension was
controlled by oral antihypertensive agents. Those who had
vitamin D deficiency were started on vitamin D oral sup-
plements in the hospital. Sputum samples were sent regu-
larly to the microbiology laboratory on a weekly basis for
AFB testing, and the highest bacillary load was recorded
based on WHO/International Union Against Tuberculosis
and Lung Disease (IUATLD) system [18]. This study was
approved by Hamad Medical Corporation institutional re-
view board. All procedures performed in this study were
in accordance with the 1964 Helsinki declaration. For this
type of study formal consent is not required.
Study design
In this retrospective cohort study, we compared FDC and
ST in terms of effectiveness and safety. We included all
patients diagnosed with PTB based on the positive sputum
AFB results, admitted to the hospital between December
2012 and November 2014, and 18 years old or more.
Patients with mycobacteria resistant to the first-line
anti-TB were excluded.
Data collection
We identified patients from the hospital admission data-
base, while medical records and laboratory and pharmacy
databases were used to collect patients’ demographics, co-
morbidities (e.g. hypertension and diabetes), vitamin D
levels, anti-TB regimens and adverse events (cutaneous,
gastric, musculoskeletal, hepatic, visual, and hyperurice-
mia), and time to negative sputum AFB.






FDC, mg ST, mg
INH RIF PZA EMB INH RIF PZA EMB
<35 2 150 300 800 550 150 300 750 800
35–54 3 225 450 1200 825 225 450 1000 1200
>54 4 300 600 1600 1100 300 600 1500 1600
EMB ethambutol, FDC fixed-dose combination, INH isoniazid, PZA pyrazinamide,
RIF rifampin, ST separate tablets
aFDC tablet contains rifampin 150 mg, isoniazid 75 mg, pyrazinamide 400 mg,
and ethambutol 275 mg
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Hepatotoxicity was defined as elevation in transami-
nases 3 times or more above upper normal limit (>120
units/L). Cutaneous adverse events were defined as rash
or itching, and were identified from physician notes and
antihistamine administration once reported by the pa-
tient. Gastric adverse events including nausea, vomiting,
or epigastric and abdominal pain were identified. Hyper-
uricemia was defined as any uric acid level above 416
micromol/L. Visual adverse events including blurred vi-
sion, color blindness, or eye pain were recorded when
reported by the patient, in addition to the musculoskel-
etal adverse events such as muscular and joint pain. The
primary outcome was to assess the effectiveness of both
regimens by assessing time to negative sputum AFB con-
firmed by two consecutive smears. Secondary outcomes
were to assess the safety of regimens by comparing inci-
dence of adverse events between regimens and to com-
pare the effectiveness and safety of both regimens in the
different subgroups.
Statistical analysis
Continuous data were reported as means and standard
deviation (SD), whereas categorical data were reported as
frequency and percentages. We used student t-test to
compare continuous data, and Chi-square test to compare
categorical data between the two groups of comparison.
We set the significance level of 0.05. All statistical analyses
were performed using SPSS 19.0 (SPSS Inc. Chicago, IL).
Results
A total of 148 patients were included in this study
(Table 2). The mean (±SD) for age and body mass index
(BMI) were 33.9 ± 10.1 years and 20.4 ± 3.1 kg/m2, re-
spectively. Patients were mostly of male gender (85.8%)
and of Asian ethnicity (87%). A total of 33 patients had
diabetes, and 7 patients had hypertension on admission.
Nine patients (6%) had vitamin D level <10 ng/ml, and
94 patients (64%) between 10–29 ng/ml. There were 90
patients (61%) and 58 patients (39%) in FDC and ST
groups, respectively. Asians accounted for 88.9% in the
FDC group and 84.5% in the ST group. The numbers of
smokers and male patients were higher in the FDC
group than the ST group (44.4% vs. 19%, p = 0.001) and
(92.2% vs. 75.9%, p = 0.005), respectively. There were no
other differences between groups in all other baseline
characteristics.
Effectiveness
There was no statistical difference in the mean time to
achieve negative sputum AFB in the FDC and ST regi-
mens groups (Table 3). Even though the objective of this
study was not to compare the response to treatment in
patients with diabetes; it is worth noting that among the
33 patients with diabetes, 19 (57.6%) received the FDC
while the remaining 14 patients (42.4%) received ST. Pa-
tients with Diabetes receiving FDC had faster conversion
to negative sputum smear compared to those receiving
ST (31 ± 12 vs. 49.4 ± 30.9 days, p = 0.05). Also, when we
compared diabetic patients with different AFB load, only
those who received FDC and had AFB +++ (n = 8)
showed significant faster sputum conversion compared
to those who received ST (n = 6) (37.8 ± 14.2 vs. 72.5 ±
27.7 days, p = 0.01). When compared to non-diabetics,
patients with diabetes needed longer time for sputum
AFB conversion (38.8 vs. 30.2 days, p = 0.03). Time to
negative smear was not significantly different between
FDC and ST in any of the other subgroups.
Safety
The incidence of adverse events between both groups is
shown in Fig. 1. None showed statistically significant dif-
ference except for visual adverse events that were higher
in ST group (5.2% vs. 0%, p = 0.03). There was a tendency
towards increase in musculoskeletal adverse events in ST
Table 2 Baseline characteristics and doses of anti-tuberculosis
medications
FDC (n = 90) ST (n = 58)
Age in years, mean ± SD 34.3 ± 10.1 33.4 ± 10.2
Male gender, n (%) 83 (92.2) 44 (75.9)
Asian nationalitya, n (%) 80 (88.9) 49 (84.5)
BMI (kg/m2), mean ± SDb 20.3 ± 3.1 20.5 ± 3.2
Diabetes, n (%) 19 (21.1) 14 (24.1)
Hypertension, n (%) 4 (4.4) 3 (5.2)
Smoking, n (%) 40 (44.4) 11 (19)
Vitamin D level (ng/ml), mean ± SDc 19.7 ± 10 18.5 ± 6.2
Isoniazid (mg/kg), mean ± SD 4.8 ± 0.4 5.5 ± 1
Rifampin (mg/kg), mean ± SD 9.6 ± 0.9 10 ± 1.2
Pyrazinamide (mg/kg), mean ± SD 25.8 ± 2.2 23.4 ± 2.3
Ethambutol (mg/kg), mean ± SD 17.7 ± 1.7 17 ± 5.7
+++ AFB load, n (%) 34 (37.8) 24 (41.4)
AFB acid-fast bacilli, BMI body mass index, FDC fixed-dose combination, ST
separate tablets
aSouth Asian and Southeast Asian nationalities including Indian, Nepalese,
Pakistani, Bangladeshi, Sri Lankan, Indonesian, and Filipino
bData available for 81 (FDC group) and 55 (ST group) patients
cData available for 68 (FDC group) and 49 (ST group) patients
Table 3 Mean time to negative sputum smear among groups
in days
Patients groups FDC, mean ± SD (n) ST, mean ± SD (n) p-valuea
All patients 29.9 ± 18.3 (90) 35.6 ± 23 (58) 0.12
Diabetic 31 ± 12 (19) 49.4 ± 30.9 (14) 0.05
Non-diabetics 29.6 ± 19.7 (71) 31.2 ± 18.2 (44) 0.67
Smokers 26.6 ± 11.3 (40) 35.8 ± 22.9 (11) 0.22
FDC fixed-dose combination, ST separate tablets, NS non-significant
aUsing independent t-test
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group (22% vs. 11%, p = 0.06). Subgroup analysis of
adverse events between groups showed that in non-
diabetics, ST group had higher incidence of musculoskel-
etal adverse events (25% vs. 9.9%, p = 0.03), while other
adverse events showed no difference. Diabetic patients
had more hepatotoxic and gastrointestinal adverse events
compared to non-diabetics (18.2% vs. 5.2%, p = 0.016) and
(54.5% vs. 16.5% p < 0.001), respectively.
Discussion
This is the first study to compare the safety and efficacy
of the four-drug FDC (Rifafour) and ST regimens on the
population living in Qatar. Both regimens showed simi-
lar efficacy and safety profiles. The efficacy was observed
by time to negative sputum AFB during hospitalization
and the safety was reported in terms of commonly seen
adverse events for TB medications. Such results are con-
sistent with what has been reported in previous trials
with few exceptions. For instance, time to negative AFB
was tested in the outpatient setting at 2, 4 and 6 months
whereas in the current study, it was assessed upon diag-
nosis and weekly. Also, safety parameters such as mus-
culoskeletal and visual disturbances were observed more
in the ST group compared to the FDC group, noting a
statistically significance difference in terms of visual
disturbances [19, 20]. Bartacek and colleagues studied
Rimstar®, a 4-FDC drug, where they compared it to ST
regimens in terms of efficacy, safety and patients’ accept-
ability in an open multicenter, multinational study.
Sputum smear conversion was tested at 2, 4, and 6 months
then at follow up appointments at 9 and 12 months. The
two groups showed similar efficacy, and non-inferiority of
4-FDC to ST was proved. In terms of safety, 4-FDC group
showed to have less gastrointestinal disturbance such as
nausea and vomiting (P = 0.03), liver and biliary disorders
such as hepatitis and jaundice (p = 0.04), and general dis-
orders such as headache and asthenia (P = 0.01) than ST
group. Acceptability and convenience was proven to be
better with the FDC group than the ST group [19]. In the
study C randomized controlled trial, Lienhardt and col-
leagues evaluated the safety and efficacy of 4- FDC regi-
men compared to ST in TB patients. Cultures were taken
at 2 months and 18 months after the initiation of treat-
ment. FDC showed non-inferiority to ST regimen in terms
of efficacy. Safety was measured by looking at adverse
events in both groups for the first 2 months of treatment.
In terms of safety parameters such as dermatologic, rheu-
matologic, hepatic, or gastrointestinal disorders, there was
no significant difference between the FDC and ST group
(p = 0.1) [21]. Wu and colleagues conducted a prospective,
open label randomized trial comparing FDC and ST regi-
mens in terms of safety and efficacy. Direct observed ther-
apy (DOT) was adapted 5 days a week, while doses were
self-administered on weekends. The FDC group received
Rifater® (Gruppo Lepetit SPA, Lainate, Italy) which con-
tains (INH/RIF/PZA: 80/120/250 mg per tablet) and EMB
for the first two months, followed by Rifinahs® (Gruppo
Lepetit SPA, Lainate, Italy) which contains (INH/RIF 100/
150 mg per tablet) and EMB for an additional four
months or longer. In this study the FDC was a 3 FDC in
addition to ethambutol as a separate drug. Efficacy was
assessed by examining the sputum culture at 2 and
Fig. 1 FDC, fixed-dose combination; ST, separate tablets. * p = 0.03 (Chi-square test)
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4 months and then reexamined at 6 months and one year.
Both groups showed similar efficacy. In terms of safety,
FDC groups showed a transient increase in bilirubin level
during treatment compared to ST group [20]. Systemic re-
views comparing fixed-dose combination therapy to separ-
ate drug combinations were conducted. These reviews
had similar conclusions indicating no advantage in terms
of efficacy between the two regimens for patients with
active TB [22, 23].
In terms of safety, as noted in the results visual ad-
verse events were found higher in the ST group than the
FDC group. This could be related to the EMB dose used
in the ST regimen compared to the FDC regimen where
patients in the ST regimen received a weight based dose
estimated around 20 mg/kg whereas in the FDC group re-
ceived a 15 mg/kg dose. Griffith and colleagues assessed
EMB ocular toxicity in patients receiving mycobacterium
avium complex (MAC) treatment [24]. A mean dose of
16.1 mg/kg was administered either daily for three times
per week for ± 10.8 months. Patients suffered from revers-
ible ocular toxicity where baseline ocular went back to
normal status after discontinuation of EMB. The re-
searchers concluded that three times per week EMB ad-
ministration was associated with less ocular toxicity than
daily EMB administration.
When a subgroup analysis was conducted, hepatotox-
icity and gastrointestinal adverse effects incidence was
higher in diabetic patients when compared to non-
diabetics. This finding is in line with Wu and colleagues
where a high number of diabetic patients and an in-
crease in bilirubin was noted [20]. However, they did not
correlate the incidence of increase in bilirubin with the
existence of diabetes as a chronic disease among the
participants. On the other hand, data regarding diabetes
effect on efficacy of TB treatment are limited. In one
study, diabetic patients had more positive sputum mi-
croscopy after 2 months compared to non-diabetics
(18% vs. 10%, adjusted OR 1.90; 95% CI, [0.82–4.42]), and
22.2% of diabetic patients had positive sputum culture
after 6 months compared to 9.6% who were non-diabetics
(adjusted OR, 7.65; 95% CI, [1.89–30.95]) [25].
In the current study, patients with diabetes needed lon-
ger time for sputum conversion, which is consistent with
previous studies [26–28]. Previous studies conducted on
diabetic patients with TB infection showed a slow re-
sponse to the treatment and lower levels of anti-TB medi-
cations compared to non-diabetics [29–31]. However,
Ruslami et al. conducted a pharmacokinetic study on 36
patients, 18 of them were diabetic, and concluded that
diabetes does not alter pharmacokinetics of anti-TB medi-
cations during the intensive treatment phase [32].
There were certain limitations for this study. This was
performed retrospectively where the number of patients
was relatively small. Hence, a prospective randomized
study or a retrospective study with larger number of pa-
tients and a close follow-up is warranted in order to
confirm the current findings. Another limitation is that
the majority of the included patients were Asian males.
This may not reflect the general population with pul-
monary TB; however, it reflects the infected patients in
Qatar who are young foreign workers. In similar studies,
the ratio of male to female was smaller than the current
study [19, 20]. Furthermore, the study was not powered
to detect the difference between diabetic and non-
diabetic patients in terms of efficacy and safety. Those
finding were found part of a subgroup analysis. Since it
is a retrospective study, another limitation is the lack of
AFB data at 2, 4 and 6 months that the study group
could not obtain.
Conclusion
Pulmonary TB patients treated with a 4-FDC using
Rifafour® showed to have similar response to treatment
to those treated with ST while maintaining a similar
safety profile, except for visual adverse events that were
more noticed in the ST than FDC. Diabetic patients
treated with FDC had a faster AFB conversion than those
treated with ST regimen. Also, more hepatotoxicity and
gastric adverse events were seen among patients with
diabetes. Since the current study was not powered to
compare the efficacy and safety of FDC to ST, further in-
vestigation in this population is warranted.
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